<DOC>
	<DOCNO>NCT00287079</DOCNO>
	<brief_summary>The primary objective initiative ass effectiveness subcutaneous ( sc ) interferon ( IFN ) beta - 1a , ( Rebif速 ) , versus No Treatment delay conversion Clinically Definite Multiple Sclerosis ( CDMS ) - define occurrence second exacerbation - 96 week subject present Clinically Isolated Syndrome ( CIS ) accompany abnormal magnetic resonance imaging ( MRI ) . The secondary objective : - Assess effectiveness sc IFN beta - 1a ( Rebif速 ) therapy reduce proportion patient CIS convert CDMS - Assess safety sc IFN beta - 1a ( Rebif速 ) patient CIS</brief_summary>
	<brief_title>A Prospective Study Looking Use Rebif速 Subjects With Clinically Isolated Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Subject must experience first clinical episode suggestive demyelinating disease Subject must present abnormal MRI display least 3 T2 weight hyperintense lesion typical multiple sclerosis ( MS ) Subject must great equal 18 year old Subject must onset clinical attack within last 120 day Subject must give write informed consent Female subject must neither pregnant breast feeding , must childbearing potential define either : Being postmenopausal surgically sterile Using hormonal contraceptive , intrauterine device , diaphragm spermicide condom spermicide duration study Subjects elect treatment : Subject must eligible Interferonbeta 1a therapy Subject evidence neurological disease could explain his/her symptomatology Subject pregnant lactation Subject suffer intercurrent autoimmune disease Subject suffer major medical psychiatric illness opinion investigator create undue risk subject could affect compliance procedure require study Subject receive immunomodulatory immunosuppressive therapy ( include limit cyclophosphamide , cyclosporine , methotrexate , azathioprine , linomide , mitoxantrone , teriflunomide , natalizumab , laquinimod , campath ) , within 12 month study day 1 Subjects elect treatment : Subject inadequate liver function , define total bilirubin , aspartate transaminase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase &gt; 2.5 time upper limit normal value Subject inadequate bone marrow reserve , define white blood cell count le 0.5 time low limit normal Subject know allergy IFN excipients drug product</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>